Investors & Media

Press Releases

Press Releases

Date Title View
Toggle Summary Sage Therapeutics to Present at the Cowen & Co. 40th Annual Health Care Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 24, 2020-- Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present at
View HTML
Toggle Summary Sage Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, February 27, 2020
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 10, 2020-- Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced it will host a live webcast on
View HTML
Toggle Summary Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 4, 2020-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that on Monday, February 3,
View HTML
Toggle Summary Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 3, 2020-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that on Thursday, January 2,
View HTML
Toggle Summary Sage Therapeutics to Present at J.P. Morgan Healthcare Conference on Monday, January 13, 2020
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 23, 2019-- Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present at
View HTML
Toggle Summary Sage Therapeutics Announces Planned Progression of SAGE-718 to Phase 2 in Huntington's Disease and Presentations at the 2019 Annual Meeting of the American College of Neuropsychopharmacology (ACNP)
Three poster presentations highlight the role of NMDA receptor dysfunction in Huntington’s Disease related cognitive impairment and potential for positive cognitive effects with SAGE-718 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 10, 2019-- Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical
View HTML
Toggle Summary Sage Therapeutics Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder
MOUNTAIN Study did not meet primary endpoint at Day 15 Statistical significance on HAM-D scale achieved at Days 3, 8 and 12; preliminary data from long-term follow-up suggest maintenance of effect on depressive symptoms Statistical significance achieved at Days 3, 8, 12 and 15 in patients with
View HTML
Toggle Summary Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 3, 2019-- Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that on Monday, December 2,
View HTML
Toggle Summary Sage Therapeutics Announces Third Quarter 2019 Financial Results and Highlights Pipeline and Business Progress
ZULRESSO™ (brexanolone) CIV injection revenues of $1.5M in third quarter Enrollment completed in SAGE-217 Phase 3 MOUNTAIN and SHORELINE studies with topline data expected in 4Q 2019 and 2020, respectively Planning to expand pipeline with two new GABA and NMDA clinical-stage assets Conference call
View HTML
Toggle Summary Sage Therapeutics to Present at the Stifel 2019 Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 11, 2019-- Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present at
View HTML